Unicycive Therapeutics, Inc. UNCY

4.70 (0.11) (2.29%) as of 25 Sep
Market cap
$134.0M
P/E
0.0×
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — — — — 0.00 0.00 — —
P/S ratio
— — — — — 0.00 0.00 — —
P/FCF ratio
— — — — — 0.00 0.00 — —
P/Operating CF
— — — — — (1.24) (4.90) — —
P/B ratio
— — — — — 0.00 0.00 — —
Price to Tangible BV
— — — — — 0.00 0.00 — —
EV/Sales
— — — — — 0.00 0.00 — —
EV/EBITDA
— — — — — 0.00 0.00 — —
EV/Operating CF
— — — — — (0.46) (0.68) — —
EV/FCF
— — — — — (0.46) (0.68) — —
Quick Ratio
— 0.02 0.02 0.00 7.88 0.14 0.55 1.08 2.18
Current Ratio
— 0.02 0.02 0.07 8.75 0.81 0.76 1.28 2.59
Net Debt/EBITDA
— (1.07) (0.24) (0.54) 1.94 0.02 0.47 0.83 1.43
Debt/Assets
0.00% 3,610.34% 2,421.05% 483.33% 0.81% 5.50% 0.00% 0.00% 0.00%
Debt/Equity
— (0.87) (0.52) (0.37) 0.01 (0.33) 0.00 0.00 0.00
Asset Turnover
— 0.00 0.00 0.00 0.00 0.09 0.08 0.00 0.00
Operating CF/Net income
— 0.69 0.54 0.64 0.58 0.87 0.58 0.76 1.18
Capex/Depreciation
— — 0.00 0.00 (0.06) (0.01) (0.04) (0.17) (0.04)
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 0.00% 207.18% 127.37% (145.04%) (225.47%) 1,469.52% (2,088.57%) (141.14%)
ROA
— (7,724.14%) (9,020.83%) (2,030.49%) (105.73%) (167.50%) (369.35%) (164.96%) (65.73%)
ROIC
— 0.00% 0.00% 0.00% (10,018.97%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— 92.87% 244.91% 84.76% (61.33%) 2,922.01% 764.44% (547.94%) (88.25%)
Average Days of Receivables
— — — — — 0.00 0.00 — —
Research and Development Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 1,307.68% 1,911.41% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 690.54% 1,266.22% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— — 0.00% 0.00% 0.00% 110.09% 261.78% 0.00% 0.00%
Graham Net Nets
— — — — — (0.08) (0.21) — —
Graham Number
— — — — — 9.14 23.27 — —
Earnings Yield
— — — — — (240.00%) (174.94%) — —
Free Cash Flow Yield
— — — — — (207.92%) (84.15%) — —
Revenue per Share
— 0.00 0.00 0.00 0.00 0.63 0.28 0.00 0.00
Operating CF per Share
— (0.05) (1.45) (1.72) (4.94) (10.39) (7.45) (4.27) (1.97)
Capex per Share
— 0.00 0.00 0.00 (0.02) 0.00 0.00 (0.01) 0.00
Free Cash Flow per Share
— (0.05) (1.45) (1.72) (4.96) (10.40) (7.46) (4.28) (1.97)
Cash per Share
— 0.00 0.02 0.00 14.20 0.30 3.95 3.90 2.60
Shareholders Equity per Share
— (0.08) (1.09) (3.14) 14.12 (0.31) (1.55) 1.11 1.90
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (0.08) (1.09) (3.14) 14.12 (0.31) (1.55) 1.11 1.90
Free Cash Flow
— (0.77) (1.18) (1.46) (5.80) (15.65) (18.29) (28.65) (31.34)
Working Capital
— (1.21) (0.88) (2.67) 16.31 (0.64) (4.13) 6.83 30.02
Capital Expenditures
— — — — (0.03) 0.00 (0.01) (0.07) (0.02)
Net Current Asset Value
— (1.21) (0.88) (2.67) 16.15 (0.64) (4.60) 6.71 30.02
EV/EBIT
— — — — — 0.00 0.00 — —
Capex to Sales
— — — — 0.00 0.00 0.02 0.00 0.00
Net Profit Margin
— 0.00% 0.00% 0.00% 0.00% (1,898.84%) (4,653.48%) 0.00% 0.00%
Price to Operating Income
— — — — — 0.00 0.00 — —
Other line items
Depreciation/Fixed assets
— — 0.00 0.00 17.89 7.32 10.92 5.71 8.67
Cash ROIC
— 578.36% 287.53% 86.59% (17.45%) (10,884.03%) (310.74%) (85.34%) (43.91%)
Accounts Receivable Turnover
— — — — — 0.00 0.00 — —
Accounts Payable Turnover
— — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — — 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — — 0.00 0.00 — — —
Average Payables
— — 0.19 0.25 0.46 0.82 0.87 0.95 0.72
Average Assets
— 0.01 0.02 0.11 9.47 10.78 8.50 22.93 40.40
Average Common Equity
— — (1.04) (1.78) 6.91 8.01 (2.14) 1.81 18.81

Fold the line items

Columns are period end dates